KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EPS (Weighted Average and Diluted) (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed EPS (Weighted Average and Diluted) for 13 consecutive years, with -$1.31 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 55.95% to -$1.31 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.36 through Dec 2025, down 44.37% year-over-year, with the annual reading at -$4.36 for FY2025, 44.85% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$1.31 at Xenon Pharmaceuticals, down from -$1.15 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.35 in Q1 2022, with the low at -$1.31 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.71, with a median of -$0.64 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 80.0% in 2023, then increased 1.59% in 2024.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.48 in 2021, then fell by 18.75% to -$0.57 in 2022, then decreased by 12.28% to -$0.64 in 2023, then plummeted by 31.25% to -$0.84 in 2024, then tumbled by 55.95% to -$1.31 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$1.31, -$1.15, and -$1.07 for Q4 2025, Q3 2025, and Q2 2025 respectively.